Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
10.13 USD | +0.30% | +0.40% | +0.70% |
Financials (USD)
Sales 2024 * | 41.41M | Sales 2025 * | 41.59M | Capitalization | 1.37B |
---|---|---|---|---|---|
Net income 2024 * | -571M | Net income 2025 * | -585M | EV / Sales 2024 * | 14.7 x |
Net cash position 2024 * | 758M | Net cash position 2025 * | 681M | EV / Sales 2025 * | 16.5 x |
P/E ratio 2024 * |
-2.41
x | P/E ratio 2025 * |
-2.55
x | Employees | 587 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.71% |
Latest transcript on Vir Biotechnology, Inc.
1 day | +0.30% | ||
1 week | +0.40% | ||
Current month | -9.88% | ||
1 month | -12.67% | ||
3 months | -1.55% | ||
6 months | +9.99% | ||
Current year | +0.70% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | - | |
Sung Lee
DFI | Director of Finance/CFO | 53 | 23-03-26 |
Jennifer Towne
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Charles Sigal
BRD | Director/Board Member | 72 | 20-07-01 |
Robert Perez
BRD | Director/Board Member | 59 | 16-12-31 |
Robert More
BRD | Director/Board Member | 56 | 16-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
12.90% | 227 M€ | +6.28% | - | |
0.63% | 29 M€ | +0.33% | ||
0.58% | 26 M€ | +0.78% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 10.13 | +0.30% | 738,256 |
24-03-27 | 10.1 | +1.30% | 995,069 |
24-03-26 | 9.97 | -0.30% | 603,634 |
24-03-25 | 10 | -0.50% | 442,588 |
24-03-22 | 10.05 | -0.40% | 511,002 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.70% | 1.37B | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |